-
-
-
-
-
-
-
Harmony Biosciences (HRMY) Receives U.S. Food And Drug Administration Orphan Drug Designation For Pitolisant In Prader-willi Syndrome
-
-
-
-
-
-
-
Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results
-
-
-
-
-
-
-
HARMONY BIOSCIENCES ANNOUNCES EXTENSION OF TENDER OFFER TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.
-
-
-
-
-
-
-
HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.
-
-
-
-
-
-
-
HARMONY BIOSCIENCES ANNOUNCES PLANS TO INITIATE PHASE 3 REGISTRATIONAL STUDY OF PITOLISANT IN PRADER-WILLI SYNDROME FOLLOWING POSITIVE END-OF-PHASE 2 MEETING WITH THE U.S. FOOD AND DRUG ADMINISTRATION
-
-
-
-
-
-
-
Harmony Biosciences Reports First Quarter 2023 Financial Results and Business Updates
-
-
-
-
-
-
-
HARMONY BIOSCIENCES APPOINTS JEFFREY M. DAYNO, MD AS INTERIM CEO AND EXPANDS ROLE OF JEFF ARONIN TO EXECUTIVE CHAIRMAN
-
922,461 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All